Background: Via promoter hypermethylation in gliomas, the MGMT gene is epigenetically silenced and this alteration has emerged as a important therapeutic response predictor. The current study was aimed at correlating O6-methylguanine-DNAmethyltransferase (MGMT promoter gene) methylation status with response to alkylating agent-based therapy in high-grade gliomas Methods: For MGMT promoter methylation by methylation-specific PCR, 20 cases of high-grade glioma were analysed. Treatment response and overall survival have been reported and data analysed. Results: MGMT promoter methylation was observed by methylation-specific PCR in 60 percent of gliomas. Mean survival time was significantly higher for glioblastoma patients undergoing adjuvant therapy in patients with MGMT promoter methylation (P= 0.035) and methylation status was an independent predictive factor associated with improved prognosis.Discussion and Conclusion: A more accurate indicator of response to adjuvant therapy and prognosis of high-grade gliomas was MGMT promoter methylation status. Irinotecan and bevacizumab were administered to a subset of patients in the second line environment, and patients with unmethylated MGMT tended to do better than the methylated MGMT promotor community.
Author(s) Details
Vinu Sarathy
Department of medical oncology- HealthCare Global Enterprises Ltd,
Bangalore, India.
B. J. Srinivasa
Department of medical oncology- HealthCare Global Enterprises Ltd,
Bangalore, India.
Bhanu Lalkota
Department of medical oncology-
HealthCare Global Enterprises Ltd, Bangalore, India.
P. K. Kiran
Department of medical oncology-
HealthCare Global Enterprises Ltd, Bangalore, India.
Vishal Kulkarni
Department of medical oncology-
HealthCare Global Enterprises Ltd, Bangalore, India.
Samuel Luke Koramati
Department of medical oncology-
HealthCare Global Enterprises Ltd, Bangalore, India.
Radheshyam Naik
Department of medical oncology-
HealthCare Global Enterprises Ltd, Bangalore, India.
View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/296
No comments:
Post a Comment